348 related articles for article (PubMed ID: 24952997)
1. Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies.
Conteduca V; Aieta M; Amadori D; De Giorgi U
Crit Rev Oncol Hematol; 2014 Oct; 92(1):11-24. PubMed ID: 24952997
[TBL] [Abstract][Full Text] [Related]
2. Midkine is associated with neuroendocrine differentiation in castration-resistant prostate cancer.
Nordin A; Wang W; Welén K; Damber JE
Prostate; 2013 May; 73(6):657-67. PubMed ID: 23129424
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of neuroendocrine differentiation in prostate adenocarcinoma.
Sagnak L; Topaloglu H; Ozok U; Ersoy H
Clin Genitourin Cancer; 2011 Dec; 9(2):73-80. PubMed ID: 22035833
[TBL] [Abstract][Full Text] [Related]
4. [Neuroendocrine differentiation in prostate cancer. An unrecognized and therapy-resistant phenotype].
Bonkhoff H; Fixemer T
Urologe A; 2004 Jul; 43(7):836-42. PubMed ID: 15048555
[TBL] [Abstract][Full Text] [Related]
5. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.
Gong Y; Chippada-Venkata UD; Galsky MD; Huang J; Oh WK
Prostate; 2015 May; 75(6):616-27. PubMed ID: 25560638
[TBL] [Abstract][Full Text] [Related]
6. [Relationship of neuroendocrine differentiation to biological behavior of prostate cancer].
Wu XL; Huang KT; Chen W; Chen L; Dong L; Yu ZX
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):472-5. PubMed ID: 19567097
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy.
Sun Y; Wang BE; Leong KG; Yue P; Li L; Jhunjhunwala S; Chen D; Seo K; Modrusan Z; Gao WQ; Settleman J; Johnson L
Cancer Res; 2012 Jan; 72(2):527-36. PubMed ID: 22108827
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine differentiation in castration resistant prostate cancer. Nuclear medicine radiopharmaceuticals and imaging techniques: A narrative review.
Usmani S; Orevi M; Stefanelli A; Zaniboni A; Gofrit ON; Bnà C; Illuminati S; Lojacono G; Noventa S; Savelli G
Crit Rev Oncol Hematol; 2019 Jun; 138():29-37. PubMed ID: 31092382
[TBL] [Abstract][Full Text] [Related]
9. Prognostic effect of neuroendocrine differentiation in prostate cancer: A critical review.
Surcel CI; van Oort IM; Sooriakumaran P; Briganti A; De Visschere PJ; Fütterer JJ; Ghadjar P; Isbarn H; Ost P; van den Bergh RC; Yossepowitch O; Giannarini G; Ploussard G;
Urol Oncol; 2015 Jun; 33(6):265.e1-7. PubMed ID: 25238700
[TBL] [Abstract][Full Text] [Related]
10. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer.
Palapattu GS; Wu C; Silvers CR; Martin HB; Williams K; Salamone L; Bushnell T; Huang LS; Yang Q; Huang J
Prostate; 2009 May; 69(7):787-98. PubMed ID: 19189306
[TBL] [Abstract][Full Text] [Related]
11. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
Cox ME; Deeble PD; Lakhani S; Parsons SJ
Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001
[TBL] [Abstract][Full Text] [Related]
12. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
[TBL] [Abstract][Full Text] [Related]
13. New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma.
Sciarra A; Cardi A; Dattilo C; Mariotti G; Di Monaco F; Di Silverio F
Int J Clin Pract; 2006 Apr; 60(4):462-70. PubMed ID: 16620361
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy.
Hirano D; Okada Y; Minei S; Takimoto Y; Nemoto N
Eur Urol; 2004 May; 45(5):586-92; discussion 592. PubMed ID: 15082200
[TBL] [Abstract][Full Text] [Related]
15. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.
Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
Cancer Res; 2000 Feb; 60(3):741-8. PubMed ID: 10676662
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine transdifferentiation of prostate carcinoma cells and its prognostic significance.
Marcu M; Radu E; Sajin M
Rom J Morphol Embryol; 2010; 51(1):7-12. PubMed ID: 20191113
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma.
Abrahamsson PA; Cockett AT; di Sant'Agnese PA
Prostate Suppl; 1998; 8():37-42. PubMed ID: 9690662
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST).
Zhu Y; Liu C; Cui Y; Nadiminty N; Lou W; Gao AC
Prostate; 2014 Aug; 74(11):1086-94. PubMed ID: 24819501
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine differentiation in the progression of prostate cancer.
Komiya A; Suzuki H; Imamoto T; Kamiya N; Nihei N; Naya Y; Ichikawa T; Fuse H
Int J Urol; 2009 Jan; 16(1):37-44. PubMed ID: 19120524
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
Alberti C
G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
